Prepulse inhibition and genetic mouse models of schizophrenia

Behavioural Brain Research

Volumn 204, Issue 2, 2009, Pages 282-294

  Powell, Susan B ^a   Zhou, Xianjin ^a   Geyer, Mark A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Mouse models; Prepulse inhibition; Schizophrenia; Startle

Indexed keywords

4 AMINOBUTYRIC ACID; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; DISRUPTED IN SCHIZOPHRENIA 1 PROTEIN; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE TRANSPORTER; GENE PRODUCT; GLUTAMIC ACID; GLYCINE; METABOTROPIC RECEPTOR; MUTANT PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEU DIFFERENTIATION FACTOR; NEUROLEPTIC AGENT; PROTEIN HOMER; QUETIAPINE; RACLOPRIDE; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; VOLINANSERIN;

ANXIETY DISORDER; ARTICLE; BEHAVIOR DISORDER; DEPRESSION; DISEASE COURSE; DRUG EFFICACY; DRUG RESEARCH; DRUG SYNTHESIS; DRUG TARGETING; DRUG TREATMENT FAILURE; ENVIRONMENTAL FACTOR; GENE FUNCTION; GENE IDENTIFICATION; GENE INTERACTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC MODEL; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MENTAL DISEASE; MESOLIMBIC DOPAMINERGIC SYSTEM; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; NEGATIVE SYNDROME; NERVE CONDUCTION; NEUROLOGIC DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; POSITIVE SYNDROME; PREPULSE INHIBITION; PREVALENCE; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; SCHIZOPHRENIA; SENSORIMOTOR NEUROPATHY;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; ENVIRONMENT; GENETIC PREDISPOSITION TO DISEASE; GLUTAMIC ACID; GLYCINE; MICE; MICE, TRANSGENIC; NERVE NET; PHENOTYPE; SCHIZOPHRENIA; SENSORY GATING;

EID: 69249214145     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2009.04.021     Document Type: Article

References (219)

1. Abel K.M., Allin M.P., Hemsley D.R., and Geyer M.A. Low dose ketamine increases prepulse inhibition in healthy men. Neuropharmacology 44 (2003) 729-737
2. Almond S.L., Fradley R.L., Armstrong E.J., Heavens R.B., Rutter A.R., Newman R.J., et al. Behavioral and biochemical characterization of a mutant mouse strain lacking d-amino acid oxidase activity and its implications for schizophrenia. Mol Cell Neurosci 32 (2006) 324-334
3. Ango F., Pin J.P., Tu J.C., Xiao B., Worley P.F., Bockaert J., et al. Dendritic and axonal targeting of type 5 metabotropic glutamate receptor is regulated by homer1 proteins and neuronal excitation. J Neurosci 20 (2000) 8710-8716
4. Ballard T.M., Pauly-Evers M., Higgins G.A., Ouagazzal A.-M., Mutel V., Borroni E., et al. Severe impairment of nmda receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity. J Neurosci 22 (2002) 6713-6723
5. Barr A.M., Lehmann-Masten V., Paulus M., Gainetdinov R.R., Caron M.G., and Geyer M.A. The selective serotonin-2a receptor antagonist m100907 reverses behavioral deficits in dopamine transporter knockout mice. Neuropsychopharmacology 29 (2004) 221-228
6. Beasley C.L., and Reynolds G.P. Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr Res 24 (1997) 349-355
7. Beasley C.L., Zhang Z.J., Patten I., and Reynolds G.P. Selective deficits in prefrontal cortical gabaergic neurons in schizophrenia defined by the presence of calcium-binding proteins. Biol Psychiatry 52 (2002) 708-715
8. Benes F.M. Emerging principles of altered neural circuitry in schizophrenia. Brain Res Brain Res Rev 31 (2000) 251-269
9. Benes F.M., and Berretta S. Gabaergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 25 (2001) 1-27
10. Benes F.M., Kwok E.W., Vincent S.L., and Todtenkopf M.S. A reduction of nonpyramidal cells in sector ca2 of schizophrenics and manic depressives. Biol Psychiatry 44 (1998) 88-97
11. Benes F.M., Vincent S.L., Marie A., and Khan Y. Up-regulation of gabaa receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. Neuroscience 75 (1996) 1021-1031
12. Bitsios P., Giakoumaki S.G., Theou K., and Frangou S. Increased prepulse inhibition of the acoustic startle response is associated with better strategy formation and execution times in healthy males. Neuropsychologia 44 (2006) 2494-2499
13. Blackwood D.H., Fordyce A., Walker M.T., St Clair D.M., Porteous D.J., and Muir W.J. Schizophrenia and affective disorders-cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and p300 findings in a family. Am J Hum Genet 69 (2001) 428-433
14. Boucher A.A., Arnold J.C., Duffy L., Schofield P.R., Micheau J., and Karl T. Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of delta9-tetrahydrocannabinol. Psychopharmacology (Berl) 192 (2007) 325-336
15. Bowers Jr. M.B., and Freedman D.X. Psychedelic experiences in acute psychoses. Arch Gen Psychiatry 15 (1966) 240-248
16. Box G., and Draper N. Empirical model building and response surfaces (1987), John Wiley p. 74
17. Boyce-Rustay J.M., and Holmes A. Genetic inactivation of the nmda receptor nr2a subunit has anxiolytic- and antidepressant-like effects in mice. Neuropsychopharmacology 31 (2006) 2405-2414
18. Braff D.L., Freedman R., Schork N.J., and Gottesman I.I. Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. Schizophr Bull 33 (2007) 21-32
19. Braff D.L., Geyer M.A., and Swerdlow N.R. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156 (2001) 234-258
20. Braff D.L., Light G.A., and Swerdlow N.R. Prepulse inhibition and p50 suppression are both deficient but not correlated in schizophrenia patients. Biol Psychiatry 61 (2007) 1204-1207
21. Brody S.A., Conquet F., and Geyer M.A. Disruption of prepulse inhibition in mice lacking mglur1. Eur J Neurosci 18 (2003) 3361-3366
22. Brody S.A., Conquet F., and Geyer M.A. Effect of antipsychotic treatment on the prepulse inhibition deficit of mglur5 knockout mice. Psychopharmacology (Berl) 172 (2004) 187-195
23. Brody S.A., Dulawa S.C., Conquet F., and Geyer M.A. Assessment of a prepulse inhibition deficit in a mutant mouse lacking mglu5 receptors. Mol Psychiatry 9 (2004) 35-41
24. Brody S.A., and Geyer M.A. Interactions of the mglur5 gene with breeding and maternal factors on startle and prepulse inhibition in mice. Neurotox Res 6 (2004) 79-90
25. Brody S.A., Nakanishi N., Tu S., Lipton S.A., and Geyer M.A. A developmental influence of the N-methyl-d-aspartate receptor nr3a subunit on prepulse inhibition of startle. Biol Psychiatry 57 (2005) 1147-1152
26. Bublil E.M., and Yarden Y. The egf receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 19 (2007) 124-134
27. Burdick K.E., Hodgkinson C.A., Szeszko P.R., Lencz T., Ekholm J.M., Kane J.M., et al. Disc1 and neurocognitive function in schizophrenia. Neuroreport 16 (2005) 1399-1402
28. Cadenhead K.S., Geyer M.A., and Braff D.L. Impaired startle prepulse inhibition and habituation in patients with schizotypal personality disorder. Am J Psychiatry 150 (1993) 1862-1867
29. Cadenhead K.S., Swerdlow N.R., Shafer K.M., Diaz M., and Braff D.L. Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: evidence of inhibitory deficits. Am J Psychiatry 157 (2000) 1660-1668
30. Callicott J.H., Straub R.E., Pezawas L., Egan M.F., Mattay V.S., Hariri A.R., et al. Variation in disc1 affects hippocampal structure and function and increases risk for schizophrenia. Proc Natl Acad Sci USA 102 (2005) 8627-8632
31. Cannon T.D., Hennah W., van Erp T.G., Thompson P.M., Lonnqvist J., Huttunen M., et al. Association of disc1/trax haplotypes with schizophrenia, reduced prefrontal gray matter, and impaired short- and long-term memory. Arch Gen Psychiatry 62 (2005) 1205-1213
32. Cardno A.G., and Gottesman I.I. Twin studies of schizophrenia: from bow-and-arrow concordances to star wars mx and functional genomics. Am J Med Genet 97 (2000) 12-17
33. Caspi A., Moffitt T.E., Cannon M., McClay J., Murray R., Harrington H., et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-o-methyltransferase gene: longitudinal evidence of a gene x environment interaction. Biol Psychiatry 57 (2005) 1117-1127
34. Chambers M.S., Atack J.R., Carling R.W., Collinson N., Cook S.M., Dawson G.R., et al. An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of gabaa α5 receptors with cognition enhancing properties. J Med Chem 47 (2004) 5829-5832
35. Chen J., Lipska B.K., Halim N., Ma Q.D., Matsumoto M., Melhem S., et al. Functional analysis of genetic variation in catechol-o-methyltransferase (comt): effects on mrna, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 75 (2004) 807-821
36. Chen Y-JJ, Johnson M.A., Lieberman M.D., Goodchild R.E., Schobel S., Lewandowski N., et al. Type iii neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components. J Neurosci 28 (2008) 6872-6883
37. Chiu C.S., Brickley S., Jensen K., Southwell A., McKinney S., Cull-Candy S., et al. Gaba transporter deficiency causes tremor, ataxia, nervousness, and increased gaba-induced tonic conductance in cerebellum. J Neurosci 25 (2005) 3234-3245
38. Ciruela F., Soloviev M.M., Chan W.Y., and McIlhinney R.A. Homer-1c/vesl-1l modulates the cell surface targeting of metabotropic glutamate receptor type 1alpha: evidence for an anchoring function. Mol Cell Neurosci 15 (2000) 36-50
39. Clapcote S.J., Lipina T.V., Millar J.K., Mackie S., Christie S., Ogawa F., et al. Behavioral phenotypes of disc1 missense mutations in mice. Neuron 54 (2007) 387-402
40. Creese I. Stimulants: neurochemical, behavioural, and clinical perspectives (1983), Raven, New York
41. Creese I., Burt D.R., and Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192 (1976) 481-483
42. Crestani F., Keist R., Fritschy J.M., Benke D., Vogt K., Prut L., et al. Trace fear conditioning involves hippocampal alpha 5 gabaa receptors. Proc Natl Acad Sci 99 (2002) 8980-8985
43. Csomor P.A., Stadler R.R., Feldon J., Yee B.K., Geyer M.A., and Vollenweider F.X. Haloperidol differentially modulates prepulse inhibition and p50 suppression in healthy humans stratified for low and high gating levels. Neuropsychopharmacology 33 (2008) 497-512
44. Dawson G.R., Maubach K.A., Collinson N., Cobain M., Everitt B.J., MacLeod A.M., et al. An inverse agonist selective for {alpha}5 subunit-containing gabaa receptors enhances cognition. J Pharmacol Exp Ther 316 (2006) 1335-1345
45. Doherty J.M., Masten V.L., Powell S.B., Ralph R.J., Klamer D., Low M.J., et al. Contributions of dopamine d1, d2, and d3 receptor subtypes to the disruptive effects of cocaine on prepulse inhibition in mice. Neuropsychopharmacology 33 (2008) 2648-2656
46. Duffy L., Cappas E., Scimone A., Schofield P.R., and Karl T. Behavioral profile of a heterozygous mutant mouse model for egf-like domain neuregulin 1. Behav Neurosci 122 (2008) 748-759
47. Dulawa S.C., Gross C., Stark K.L., Hen R., and Geyer M.A. Knockout mice reveal opposite roles for serotonin 1a and 1b receptors in prepulse inhibition. Neuropsychopharmacology 22 (2000) 650-659
48. Duncan G.E., Moy S.S., Lieberman J.A., and Koller B.H. Effects of haloperidol, clozapine, and quetiapine on sensorimotor gating in a genetic model of reduced nmda receptor function. Psychopharmacology (Berl) 184 (2006) 190-200
49. Duncan G.E., Moy S.S., Lieberman J.A., and Koller B.H. Typical and atypical antipsychotic drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a genetic model of nmda receptor hypofunction. Pharmacol Biochem Behav 85 (2006) 481-491
50. Eells J.B., Lipska B.K., Yeung S.K., Misler J.A., and Nikodem V.M. Nurr1-null heterozygous mice have reduced mesolimbic and mesocortical dopamine levels and increased stress-induced locomotor activity. Behav Brain Res 136 (2002) 267-275
51. Eells J.B., Misler J.A., and Nikodem V.M. Early postnatal isolation reduces dopamine levels, elevates dopamine turnover and specifically disrupts prepulse inhibition in nurr1-null heterozygous mice. Neuroscience 140 (2006) 1117-1126
52. Fernandes C., Hoyle E., Dempster E., Schalkwyk L.C., and Collier D.A. Performance deficit of alpha7 nicotinic receptor knockout mice in a delayed matching-to-place task suggests a mild impairment of working/episodic-like memory. Genes Brain Behav 5 (2006) 433-440
53. Foa L., Rajan I., Haas K., Wu G.Y., Brakeman P., Worley P., et al. The scaffold protein, homer1b/c, regulates axon pathfinding in the central nervous system in vivo. Nat Neurosci 4 (2001) 499-506
54. Fornai F., Chen K., Giorgi F.S., Gesi M., Alessandri M.G., and Shih J.C. Striatal dopamine metabolism in monoamine oxidase b-deficient mice: a brain dialysis study. J Neurochem 73 (1999) 2434-2440
55. Francis D.D., Szegda K., Campbell G., Martin W.D., and Insel T.R. Epigenetic sources of behavioral differences in mice. Nat Neurosci 6 (2003) 445-446
56. Freedman R., Adler L.E., and Leonard S. Alternative phenotypes for the complex genetics of schizophrenia. Biol Psychiatry 45 (1999) 551-558
57. Freedman R., Olincy A., Ross R.G., Waldo M.C., Stevens K.E., Adler L.E., et al. The genetics of sensory gating deficits in schizophrenia. Curr Psychiatry Rep 5 (2003) 155-161
58. Gainetdinov R.R., Wetsel W.C., Jones S.R., Levin E.D., Jaber M., and Caron M.G. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 283 (1999) 397-401
59. Gallinat J., Bajbouj M., Sander T., Schlattmann P., Xu K., Ferro E.F., et al. Association of the g1947a comt (val(108/158)met) gene polymorphism with prefrontal p300 during information processing. Biol Psychiatry 54 (2003) 40-48
60. Garzya V., Forbes I.T., Gribble A.D., Hadley M.S., Lightfoot A.P., Payne A.H., et al. Studies towards the identification of a new generation of atypical antipsychotic agents. Bioorg Med Chem Lett 17 (2007) 400-405
61. Gerdjikov T.V., Rudolph U., Keist R., Möhler H., Feldon J., and Yee B.K. Hippocampal [alpha]5 subunit-containing gabaa receptors are involved in the development of the latent inhibition effect. Neurobiol Learn Mem 89 (2008) 87-94
62. Gerlai R., Pisacane P., and Erickson S. Heregulin, but not erbb2 or erbb3, heterozygous mutant mice exhibit hyperactivity in multiple behavioral tasks. Behav Brain Res 109 (2000) 219-227
63. Geyer M.A., and Ellenbroek B. Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27 (2003) 1071-1079
64. Geyer M.A., Krebs-Thomson K., Braff D.L., and Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156 (2001) 117-154
65. Geyer M.A., and Markou A. The role of preclinical models in the development of psychotropic drugs. In: Davis K.L., Charney D., Coyle J.T., and Nemeroff C.B. (Eds). Neuropsychopharmacology: the fifth generation of progress (2002), Lippincott, Williams & Wilkins 445-455
66. Geyer M.A., McIlwain K.L., and Paylor R. Mouse genetic models for prepulse inhibition: an early review. Mol Psychiatry 7 (2002) 1039-1053
67. Geyer M.A., and Moghaddam B. Animal models relevant to schizophrenia disorders. In: Charney D., Coyle J., Davis K., and Nemeroff C.B. (Eds). Neuropsychopharmacology: the fifth generation of progress (2002), Lippincott, Williams & Wilkins 689-701
68. Giakoumaki S.G., Bitsios P., and Frangou S. The level of prepulse inhibition in healthy individuals may index cortical modulation of early information processing. Brain Res 1078 (2006) 168-170
69. Giakoumaki S.G., Roussos P., and Bitsios P. Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT val158met polymorphism. Neuropsychopharmacology 33 (2008) 3058-3068
70. Giros B., Jaber M., Jones S.R., Wightman R.M., and Caron M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379 (1996) 606-612
71. Goff D.C., Henderson D.C., Evins A.E., and Amico E. A placebo-controlled crossover trial of d-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry 45 (1999) 512-514
72. Goff D.C., Tsai G., Levitt J., Amico E., Manoach D., Schoenfeld D.A., et al. A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 56 (1999) 21-27
73. Goff D.C., Tsai G., Manoach D.S., and Coyle J.T. Dose-finding trial of d-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 152 (1995) 1213-1215
74. Gogos J.A., Morgan M., Luine V., Santha M., Ogawa S., Pfaff D., et al. Catechol-o-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci USA 95 (1998) 9991-9996
75. Gogos J.A., Santha M., Takacs Z., Beck K.D., Luine V., Lucas L.R., et al. The gene encoding proline dehydrogenase modulates sensorimotor gating in mice. Nat Genet 21 (1999) 434-439
76. Golimbet V., Gritsenko I., Alfimova M., Lebedeva I., Lezheiko T., Abramova L., et al. Association study of comt gene val158met polymorphism with auditory p300 and performance on neurocognitive tests in patients with schizophrenia and their relatives. World J Biol Psychiatry 7 (2006) 238-245
77. Golub M.S., Germann S.L., and Lloyd K.C. Behavioral characteristics of a nervous system-specific erbb4 knock-out mouse. Behav Brain Res 153 (2004) 159-170
78. Gothelf D., Schaer M., and Eliez S. Genes, brain development and psychiatric phenotypes in velo-cardio-facial syndrome. Dev Disabil Res Rev 14 (2008) 59-68
79. Gottesman I.I. Schizophrenia genesis (1991), W.H. Freeman, New York
80. Gould T.D., and Gottesman I.I. Psychiatric endophenotypes and the development of valid animal models. Genes Brain Behav 5 (2006) 113-119
81. Gouzoulis-Mayfrank E., Habermeyer E., Hermle L., Steinmeyer A.M., Kunert H.J., and Sass H. Hallucinogenic drug induced states resemble acute endogenous psychoses: results of an empirical study. Eur Psychiatry 13 (1998) 399-406
82. Gray L., van den Buuse M., Scarr E., Dean B., and Hannan A.J. Clozapine reversess chizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-D-aspartic acid receptor up-regulation. Int J Neuropsychopharmacol 12 (2009) 45-60
83. Green M.F., Butler P.D., Chen Y., Geyer M.A., Silverstein S., Wynn J.K., et al. Perception measurement in clinical trials of schizophrenia: promising paradigms from cntrics. Schizophr Bull 35 (2009) 163-181
84. Greenwood T.A., Braff D.L., Light G.A., Cadenhead K.S., Calkins M.E., Dobie D.J., et al. Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. Arch Gen Psychiatry 64 (2007) 1242-1250
85. Harrison P.J., and Law A.J. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry 60 (2006) 132-140
86. Harrison P.J., and Owen M.J. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 361 (2003) 417-419
87. Harrison P.J., and Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 10 (2005) 40-68 image 45
88. Harte M.K., Powell S.B., Swerdlow N.R., Geyer M.A., and Reynolds G.P. Deficits in parvalbumin and calbindin immunoreactive cells in the hippocampus of isolation reared rats. J Neural Transm 114 (2007) 893-898
89. Hauser J., Rudolph U., Keist R., Mohler H., Feldon J., and Yee B.K. Hippocampal [alpha]5 subunit-containing gabaa receptors modulate the expression of prepulse inhibition. Mol Psychiatry 10 (2004) 201-207
90. Hazlett E.A., and Buchsbaum M.S. Sensorimotor gating deficits and hypofrontality in schizophrenia. Front Biosci 6 (2001) D1069-D1072
91. Hazlett E.A., Buchsbaum M.S., Haznedar M.M., Singer M.B., Germans M.K., Schnur D.B., et al. Prefrontal cortex glucose metabolism and startle eyeblink modification abnormalities in unmedicated schizophrenia patients. Psychophysiology 35 (1998) 186-198
92. Heldt S.A., Green A., and Ressler K.J. Prepulse inhibition deficits in gad65 knockout mice and the effect of antipsychotic treatment. Neuropsychopharmacology 29 (2004) 1610-1619
93. Hennah W., Tuulio-Henriksson A., Paunio T., Ekelund J., Varilo T., Partonen T., et al. A haplotype within the disc1 gene is associated with visual memory functions in families with a high density of schizophrenia. Mol Psychiatry 10 (2005) 1097-1103
94. Hikida T., Jaaro-Peled H., Seshadri S., Oishi K., Hookway C., Kong S., et al. Dominant-negative disc1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proc Natl Acad Sci USA 104 (2007) 14501-14506
95. Hitzemann R., Malmanger B., Belknap J., Darakjian P., and McWeeney S. Short-term selective breeding for high and low prepulse inhibition of the acoustic startle response; pharmacological characterization and qtl mapping in the selected lines. Pharmacol Biochem Behav 90 (2008) 525-533
96. Hoffman H.S., and Ison J.R. Reflex modification in the domain of startle. I. Some empirical findings and their implications for how the nervous system processes sensory input. Psychol Rev 87 (1980) 175-189
97. Jaubert P.J., Golub M.S., Lo Y.Y., Germann S.L., Dehoff M.H., Worley P.F., et al. Complex, multimodal behavioral profile of the homer1 knockout mouse. Genes Brain Behav 6 (2007) 141-154
98. Javitt D.C. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 9 (2004) 984-997
99. Javitt D.C., Balla A., Sershen H., and Lajtha A. A.E. Bennett research award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors. Biol Psychiatry 45 (1999) 668-679
100. Javitt D.C., Sershen H., Hashim A., and Lajtha A. Inhibition of striatal dopamine release by glycine and glycyldodecylamide. Brain Res Bull 52 (2000) 213-216
101. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148 (1991) 1301-1308
102. Johnson J.W., and Ascher P. Glycine potentiates the nmda response in cultured mouse brain neurons. Nature 325 (1987) 529-531
103. Jones D.N.C., Gartlon J.E., Minassian A., Perry W., and Geyer M.A. Developing new drugs for schizophrenia: from animals to the clinic. In: McArthur R., and Borsini R. (Eds). Animal and translational models for cns drug discovery: psychiatric disorders (2008), Elsevier, New York 199-262
104. Joober R., Zarate J.M., Rouleau G.A., Skamene E., and Boksa P. Provisional mapping of quantitative trait loci modulating the acoustic startle response and prepulse inhibition of acoustic startle. Neuropsychopharmacology 27 (2002) 765-781
105. Jurata L.W., Gallagher P., Lemire A.L., Charles V., Brockman J.A., Illingworth E.L., et al. Altered expression of hippocampal dentate granule neuron genes in a mouse model of human 22q11 deletion syndrome. Schizophr Res 88 (2006) 251-259
106. Kanahara N., Shimizu E., Ohgake S., Fujita Y., Kohno M., Hashimoto T., et al. Glycine and d: -serine, but not d: -cycloserine, attenuate prepulse inhibition deficits induced by nmda receptor antagonist mk-801. Psychopharmacology (Berl) 198 (2008) 363-374
107. Karayiorgou M., Morris M.A., Morrow B., Shprintzen R.J., Goldberg R., Borrow J., et al. Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11. Proc Natl Acad Sci USA 92 (1995) 7612-7616
108. Karl T., Duffy L., Scimone A., Harvey R.P., and Schofield P.R. Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia. Genes Brain Behav 6 (2007) 677-687
109. Karper L.P., Freeman G.K., Grillon C., Morgan III C.A., Charney D.S., and Krystal J.H. Preliminary evidence of an association between sensorimotor gating and distractibility in psychosis. J Neuropsychiatry Clin Neurosci 8 (1996) 60-66
110. Koike H., Arguello P.A., Kvajo M., Karayiorgou M., and Gogos J.A. Disc1 is mutated in the 129s6/svev strain and modulates working memory in mice. Proc Natl Acad Sci 103 (2006) 3693-3697
111. Kopin I.J. Catecholamine metabolism: basic aspects and clinical significance. Pharmacol Rev 37 (1985) 333-364
112. Krebs-Thomson K., Ruiz E.M., Masten V., Buell M., and Geyer M.A. The roles of 5-ht1a and 5-ht2 receptors in the effects of 5-meo-dmt on locomotor activity and prepulse inhibition in rats. Psychopharmacology (Berl) 189 (2006) 319-329
113. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., et al. Subanesthetic effects of the noncompetitive nmda antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51 (1994) 199-214
114. Kumari V., Fannon D., Geyer M.A., Premkumar P., Antonova E., Simmons A., et al. Cortical grey matter volume and sensorimotor gating in schizophrenia. Cortex 44 (2008) 1206-1214
115. Kumari V., Gray J.A., Geyer M.A., Ffytche D., Soni W., Mitterschiffthaler M.T., et al. Neural correlates of tactile prepulse inhibition: a functional mri study in normal and schizophrenic subjects. Psychiatry Res 122 (2003) 99-113
116. Kvajo M., McKellar H., Arguello P.A., Drew L.J., Moore H., MacDermott A.B., et al. A mutation in mouse disc1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition. Proc Natl Acad Sci USA 105 (2008) 7076-7081
117. Lachman H.M., Papolos D.F., Saito T., Yu Y.M., Szumlanski C.L., and Weinshilboum R.M. Human catechol-o-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6 (1996) 243-250
118. Le Pen G., Kew J., Alberati D., Borroni E., Heitz M.P., and Moreau J.L. Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampal-lesioned rats: reversal by glycine and a glycine transporter inhibitor. Biol Psychiatry 54 (2003) 1162-1170
119. Leonard S., Gault J., Hopkins J., Logel J., Vianzon R., Short M., et al. Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry 59 (2002) 1085-1096
120. Lewis D.A., Volk D.W., and Hashimoto T. Selective alterations in prefrontal cortical gaba neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology (Berl) 174 (2004) 143-150
121. Li W., Zhou Y., Jentsch J.D., Brown R.A., Tian X., Ehninger D., et al. Specific developmental disruption of disrupted-in-schizophrenia-1 function results in schizophrenia-related phenotypes in mice. Proc Natl Acad Sci USA 104 (2007) 18280-18285
122. Lipina T., Labrie V., Weiner I., and Roder J. Modulators of the glycine site on nmda receptors, d-serine and alx 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology (Berl) 179 (2005) 54-67
123. Lipina T., Weiss K., and Roder J. The ampakine cx546 restores the prepulse inhibition and latent inhibition deficits in mglur5-deficient mice. Neuropsychopharmacology 32 (2007) 745-756
124. Liu H., Abecasis G.R., Heath S.C., Knowles A., Demars S., Chen Y.J., et al. Genetic variation in the 22q11 locus and susceptibility to schizophrenia. Proc Natl Acad Sci USA 99 (2002) 16859-16864
125. Lominac K.D., Oleson E.B., Pava M., Klugmann M., Schwarz M.K., Seeburg P.H., et al. Distinct roles for different homer1 isoforms in behaviors and associated prefrontal cortex function. J Neurosci 25 (2005) 11586-11594
126. Low N.C., and Hardy J. What is a schizophrenic mouse?. Neuron 54 (2007) 348-349
127. Lu B.Y., Martin K.E., Edgar J.C., Smith A.K., Lewis S.F., Escamilla M.A., et al. Effect of catechol o-methyltransferase val(158)met polymorphism on the p50 gating endophenotype in schizophrenia. Biol Psychiatry 62 (2007) 822-825
128. Ludewig K., Geyer M.A., and Vollenweider F.X. Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia. Biol Psychiatry 54 (2003) 121-128
129. Ludewig S., Ludewig K., Geyer M.A., Hell D., and Vollenweider F.X. Prepulse inhibition deficits in patients with Panic Disorder. Depress Anxiety 15 (2002) 55-60
130. Mackeprang T., Kristiansen K.T., and Glenthoj B.Y. Effects of antipsychotics on prepulse inhibition of the startle response in drug-naive schizophrenic patients. Biol Psychiatry 52 (2002) 863-873
131. Mackie S., Millar J.K., and Porteous D.J. Role of disc1 in neural development and schizophrenia. Curr Opin Neurobiol 17 (2007) 95-102
132. Malhotra A.K., Adler C.M., Kennison S.D., Elman I., Pickar D., and Breier A. Clozapine blunts N-methyl-d-aspartate antagonist-induced psychosis: a study with ketamine. Biol Psychiatry 42 (1997) 664-668
133. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D., et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17 (1997) 141-150
134. Martin L.F., Kem W.R., and Freedman R. Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology (Berl) 174 (2004) 54-64
135. Martin L.F., Leonard S., Hall M.H., Tregellas J.R., Freedman R., and Olincy A. Sensory gating and alpha-7 nicotinic receptor gene allelic variants in schizoaffective disorder, bipolar type. Am J Med Genet B Neuropsychiatr Genet 144B (2007) 611-614
136. McBain C.J., and Mayer M.L. N-methyl-d-aspartic acid receptor structure and function. Physiol Rev 74 (1994) 723-760
137. McOmish C.E., Burrows E., Howard M., Scarr E., Kim D., Shin H.S., et al. Phospholipase c-beta1 knockout mice exhibit endophenotypes modeling schizophrenia which are rescued by environmental enrichment and clozapine administration. Mol Psychiatry 13 (2008) 661-672
138. Mei L., and Xiong W.C. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci 9 (2008) 437-452
139. Meincke U., Morth D., Voss T., Thelen B., Geyer M.A., and Gouzoulis-Mayfrank E. Prepulse inhibition of the acoustically evoked startle reflex in patients with an acute schizophrenic psychosis-a longitudinal study. Eur Arch Psychiatry Clin Neurosci 254 (2004) 415-421
140. Meyer U., Feldon J., Schedlowski M., and Yee B.K. Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia. Neurosci Biobehav Rev 29 (2005) 913-947
141. A receptors. J Neurochem 102 (2007) 1-12
142. Moy S.S., Perez A., Koller B.H., and Duncan G.E. Amphetamine-induced disruption of prepulse inhibition in mice with reduced nmda receptor function. Brain Res 1089 (2006) 186-194
143. O'Tuathaigh C.M., Babovic D., O'Meara G., Clifford J.J., Croke D.T., and Waddington J.L. Susceptibility genes for schizophrenia: characterisation of mutant mouse models at the level of phenotypic behaviour. Neurosci Biobehav Rev 31 (2007) 60-78
144. O'Tuathaigh C.M., Babovic D., O'Sullivan G.J., Clifford J.J., Tighe O., Croke D.T., et al. Phenotypic characterization of spatial cognition and social behavior in mice with 'knockout' of the schizophrenia risk gene neuregulin 1. Neuroscience 147 (2007) 18-27
145. Oranje B., Geyer M.A., Bocker K.B., Leon Kenemans J., and Verbaten M.N. Prepulse inhibition and p50 suppression: commonalities and dissociations. Psychiatry Res 143 (2006) 147-158
146. Oranje B., Gispen-de Wied C.C., Verbaten M.N., and Kahn R.S. Modulating sensory gating in healthy volunteers: the effects of ketamine and haloperidol. Biol Psychiatry 52 (2002) 887-895
147. Papaleo F., Crawley J.N., Song J., Lipska B.K., Pickel J., Weinberger D.R., et al. Genetic dissection of the role of catechol-o-methyltransferase in cognition and stress reactivity in mice. J Neurosci 28 (2008) 8709-8723
148. Paterlini M., Zakharenko S.S., Lai W.S., Qin J., Zhang H., Mukai J., et al. Transcriptional and behavioral interaction between 22q11.2 orthologs modulates schizophrenia-related phenotypes in mice. Nat Neurosci 8 (2005) 1586-1594
149. Paylor R., and Crawley J.N. Inbred strain differences in prepulse inhibition of the mouse startle response. Psychopharmacology 132 (1997) 169-180
150. Paylor R., Nguyen M., Crawley J.N., Patrick J., Beaudet A., and Orr-Urtreger A. Alpha7 nicotinic receptor subunits are not necessary for hippocampal-dependent learning or sensorimotor gating: a behavioral characterization of acra7-deficient mice. Learn Mem (Cold Spring Harbor, N.Y.) 5 (1998) 302-316
151. Perry W., and Braff D.L. Information-processing deficits and thought disorder in schizophrenia. Am J Psychiatry 151 (1994) 363-367
152. Perry W., Geyer M.A., and Braff D.L. Sensorimotor gating and thought disturbance measured in close temporal proximity in schizophrenic patients. Arch Gen Psychiatry 56 (1999) 277-281
153. Perry W., Minassian A., Feifel D., and Braff D.L. Sensorimotor gating deficits in bipolar disorder patients with acute psychotic mania. Biol Psychiatry 50 (2001) 418-424
154. Perry W., Minassian A., Lopez B., Maron L., and Lincoln A. Sensorimotor gating deficits in adults with autism. Biol Psychiatry 61 (2007) 482-486
155. Pletnikov M.V., Ayhan Y., Nikolskaia O., Xu Y., Ovanesov M.V., Huang H., et al. Inducible expression of mutant human disc1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia. Mol Psychiatry 13 (2007) 173-186
156. Porteous D.J., and Millar J.K. Disrupted in schizophrenia 1: building brains and memories. Trends Mol Med 12 (2006) 255-261
157. Porteous D.J., Thomson P., Brandon N.J., and Millar J.K. The genetics and biology of disc1-an emerging role in psychosis and cognition. Biol Psychiatry 60 (2006) 123-131
158. Postma P., Gray J.A., Sharma T., Geyer M., Mehrotra R., Das M., et al. A behavioural and functional neuroimaging investigation into the effects of nicotine on sensorimotor gating in healthy subjects and persons with schizophrenia. Psychopharmacology (Berl) 184 (2006) 589-599
159. Powell SB, Risbrough VB, Lehmann-Masten V, Krebs-Thomson K, Hen R, Gingrich JA, Geyer MA. The indoleamine hallucinogens, psilocin and 5meodmt, increase prepulse inhibition in mice: role of 5-ht1a and 5-ht2a receptors. Society for Neuroscience, New Orleans, LA, 2003 Abstract Viewer/Itinerary Planner, 2003, Program No. 315.7.
160. Powell S.B., Young J.W., Ong J.C., Caron M.G., and Geyer M.A. Atypical antipsychotics clozapine and quetiapine attenuate prepulse inhibition deficits in dopamine transporter knockout mice. Behav Pharmacol 19 (2008) 562-565
161. Quednow B.B., Wagner M., Mossner R., Maier W., and Kuhn K.-U. Sensorimotor gating of schizophrenia patients depends on catechol o-methyltransferase val158met polymorphism. Schizophr Bull (2008) sbn088
162. Ralph-Williams R.J., Lehmann-Masten V., and Geyer M.A. Dopamine d1 rather than d2 receptor agonists disrupt prepulse inhibition of startle in mice. Neuropsychopharmacology 28 (2003) 108-118
163. Ralph R.J., and Caine S.B. Dopamine d1 and d2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to swiss-webster, 129x1/svj, c57bl/6j, and dba/2j mice. J Pharmacol Exp Ther 312 (2005) 733-741
164. Ralph R.J., Paulus M.P., Fumagalli F., Caron M.G., and Geyer M.A. Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: differential effects of d1 and d2 receptor antagonists. J Neurosci 21 (2001) 305-313
165. Ralph R.J., Varty G.B., Kelly M.A., Wang Y.M., Caron M.G., Rubinstein M., et al. The dopamine d2, but not d3 or d4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice. J Neurosci 19 (1999) 4627-4633
166. Reynolds G.P., Abdul-Monim Z., Neill J.C., and Zhang Z.J. Calcium binding protein markers of gaba deficits in schizophrenia-postmortem studies and animal models. Neurotox Res 6 (2004) 57-61
167. Reynolds G.P., Czudek C., and Andrews H.B. Deficit and hemispheric asymmetry of gaba uptake sites in the hippocampus in schizophrenia. Biol Psychiatry 27 (1990) 1038-1044
168. Rimer M., Barrett D.W., Maldonado M.A., Vock V.M., and Gonzalez-Lima F. Neuregulin-1 immunoglobulin-like domain mutant mice: clozapine sensitivity and impaired latent inhibition. Neuroreport 16 (2005) 271-275
169. Roth B.L., Sheffler D.J., and Kroeze W.K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3 (2004) 353-359
170. Roussos P., Giakoumaki S.G., Rogdaki M., Pavlakis S., Frangou S., and Bitsios P. Prepulse inhibition of the startle reflex depends on the catechol o-methyltransferase val158met gene polymorphism. Psychol Med (2008) 1-8
171. Rudolph U., and Möhler H. Gaba-based therapeutic approaches: gabaa receptor subtype functions. Curr Opin Pharmacol 6 (2006) 18-23
172. Savonenko A.V., Melnikova T., Laird F.M., Stewart K.A., Price D.L., and Wong P.C. Alteration of bace1-dependent nrg1/erbb4 signaling and schizophrenia-like phenotypes in bace1-null mice. Proc Natl Acad Sci 105 (2008) 5585-5590
173. Schwabe K., Freudenberg F., and Koch M. Selective breeding of reduced sensorimotor gating in Wistar rats. Behav Genet 37 (2007) 706-712
174. Seeman P., and Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188 (1975) 1217-1219
175. Segal D.S., Geyer M.A., and Schuckit A. Stimulant-induced psychosis: an evaluation of animal models. In: Youdim M.B.H., Lovenberg W., Sharman D.F., and Lagnado J.R. (Eds). Essays in neurochemistry and neuropharmacology (1981), John Wiley & Sons, New York 95-130
176. Sesack S.R., Hawrylak V.A., Matus C., Guido M.A., and Levey A.I. Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J Neurosci 18 (1998) 2697-2708
177. Shen S., Lang B., Nakamoto C., Zhang F., Pu J., Kuan S.-L., et al. Schizophrenia-related neural and behavioral phenotypes in transgenic mice expressing truncated disc1. J Neurosci 28 (2008) 10893-10904
178. Shi L., Fatemi S.H., Sidwell R.W., and Patterson P.H. Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. J Neurosci 23 (2003) 297-302
179. Roussos P., Giakoumaki S.G., Rogdaki M., Pavlakis S., Frangou S., and Bitsios P. Prepulse inhibition of the startle reflex depends on the catechol O-methyltransferase Val158Met gene polymorphism. Psychol Med 38 (2008) 1651-1658
180. Sipes T.A., and Geyer M.A. 8-oh-dpat disruption of prepulse inhibition in rats: reversal with (+)way 100,135 and localization of site of action. Psychopharmacology (Berl) 117 (1995) 41-48
181. Smith S.E.P., Li J., Garbett K., Mirnics K., and Patterson P.H. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 27 (2007) 10695-10702
182. Spielewoy C., Biala G., Roubert C., Hamon M., Betancur C., and Giros B. Hypolocomotor effects of acute and daily d-amphetamine in mice lacking the dopamine transporter. Psychopharmacology (Berl) 159 (2001) 2-9
183. Spooren W., Mombereau C., Maco M., Gill R., Kemp J.A., Ozmen L., et al. Pharmacological and genetic evidence indicates that combined inhibition of nr2a and nr2b subunit containing nmda receptors is required to disrupt prepulse inhibition. Psychopharmacology (Berl) 175 (2004) 99-105
184. Stefanis N.C., Van Os J., Avramopoulos D., Smyrnis N., Evdokimidis I., Hantoumi I., et al. Variation in catechol-o-methyltransferase val158 met genotype associated with schizotype but not cognition: a population study in 543 young men. Biol Psychiatry 56 (2004) 510-515
185. Stefansson H., Petursson H., Sigurdsson E., Steinthorsdottir V., Bjornsdottir S., Sigmundsson T., et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 71 (2002) 877-892
186. Sternfeld F., Carling R.W., Jelley R.A., Ladduwahetty T., Merchant K.J., Moore K.W., et al. Selective, orally active γ-aminobutyric acida α5 receptor inverse agonists as cognition enhancers. J Med Chem 47 (2004) 2176-2179
187. Straub R.E., and Weinberger D.R. Schizophrenia genes-famine to feast. Biol Psychiatry 60 (2006) 81-83
188. Sullivan P.F., Kendler K.S., and Neale M.C. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 60 (2003) 1187-1192
189. Swerdlow N.R., Benbow C.H., Zisook S., Geyer M.A., and Braff D.L. A preliminary assessment of sensorimotor gating in patients with obsessive compulsive disorder. Biol Psychiatry 33 (1993) 298-301
190. Swerdlow N.R., Geyer M.A., and Braff D.L. Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology (Berl) 156 (2001) 194-215
191. Swerdlow N.R., Geyer M.A., Shoemaker J.M., Light G.A., Braff D.L., Stevens K.E., et al. Convergence and divergence in the neurochemical regulation of prepulse inhibition of startle and n40 suppression in rats. Neuropsychopharmacology 31 (2006) 506-515
192. Swerdlow N.R., Karban B., Ploum Y., Sharp R., Geyer M.A., and Eastvold A. Tactile prepuff inhibition of startle in children with Tourette's syndrome: in search of an "Fmri-friendly" Startle paradigm. Biol Psychiatry 50 (2001) 578-585
193. Swerdlow N.R., Light G.A., Cadenhead K.S., Sprock J., Hsieh M.H., and Braff D.L. Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function. Arch Gen Psychiatry 63 (2006) 1325-1335
194. Swerdlow N.R., Martinez Z.A., Hanlon F.M., Platten A., Farid M., Auerbach P., et al. Toward understanding the biology of a complex phenotype: rat strain and substrain differences in the sensorimotor gating-disruptive effects of dopamine agonists. J Neurosci 20 (2000) 4325-4336
195. Swerdlow N.R., Paulsen J., Braff D.L., Butters N., Geyer M.A., and Swenson M.R. Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease. J Neurol Neurosurg Psychiatry 58 (1995) 192-200
196. Swerdlow N.R., Shoemaker J.M., Platten A., Pitcher L., Goins J., and Auerbach P.P. Heritable differences in the dopaminergic regulation of sensorimotor gating. I. Apomorphine effects on startle gating in albino and hooded outbred rat strains and their f1 and n2 progeny. Psychopharmacology (Berl) 174 (2004) 441-451
197. Swerdlow N.R., Weber M., Qu Y., Light G.A., and Braff D.L. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology (Berl) 199 (2008) 331-388
198. Szumlinski K.K., Lominac K.D., Kleschen M.J., Oleson E.B., Dehoff M.H., Schwarz M.K., et al. Behavioral and neurochemical phenotyping of homer1 mutant mice: possible relevance to schizophrenia. Genes Brain Behav 4 (2005) 273-288
199. Takeuchi T., Kiyama Y., Nakamura K., Tsujita M., Matsuda I., Mori H., et al. Roles of the glutamate receptor epsilon2 and delta2 subunits in the potentiation and prepulse inhibition of the acoustic startle reflex. Eur J Neurosci 14 (2001) 153-160
200. Thaker G.K. Schizophrenia endophenotypes as treatment targets. Expert Opin Ther Targets 11 (2007) 1189-1206
201. Torkamanzehi A., Boksa P., and Joober R. Prepulse inhibition (ppi) of tactile startle response in recombinant congenic strains of mice: Qtl mapping and comparison with acoustic ppi. J Genet Genom 35 (2008) 139-151
202. Tsai G., Ralph-Williams R.J., Martina M., Bergeron R., Berger-Sweeney J., Dunham K.S., et al. Gene knockout of glycine transporter 1: characterization of the behavioral phenotype. Proc Natl Acad Sci 101 (2004) 8485-8490
203. Tsai G., Yang P., Chung L.C., Lange N., and Coyle J.T. d-Serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44 (1998) 1081-1089
204. Tunbridge E.M., Harrison P.J., and Weinberger D.R. Catechol-o-methyltransferase, cognition, and psychosis: Val158met and beyond. Biol Psychiatry 60 (2006) 141-151
205. Turetsky B.I., Calkins M.E., Light G.A., Olincy A., Radant A.D., and Swerdlow N.R. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull 33 (2007) 69-94
206. van Berckel B.N., Evenblij C.N., van Loon B.J., Maas M.F., van der Geld M.A., Wynne H.J., et al. d-Cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. Neuropsychopharmacology 21 (1999) 203-210
207. van Berckel B.N., Oranje B., van Ree J.M., Verbaten M.N., and Kahn R.S. The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects. Psychopharmacology (Berl) 137 (1998) 271-281
208. Weber M., Chang W.L., Breier M., Ko D., and Swerdlow N.R. Heritable strain differences in sensitivity to the startle gating-disruptive effects of d2 but not d3 receptor stimulation. Behav Pharmacol 19 (2008) 786-795
209. Xiao B., Tu J.C., and Worley P.F. Homer: a link between neural activity and glutamate receptor function. Curr Opin Neurobiol 10 (2000) 370-374
210. Yamashita M., Fukushima S., Shen H.W., Hall F.S., Uhl G.R., Numachi Y., et al. Norepinephrine transporter blockade can normalize the prepulse inhibition deficits found in dopamine transporter knockout mice. Neuropsychopharmacology 31 (2006) 2132-2139
211. Yavich L., Forsberg M.M., Karayiorgou M., Gogos J.A., and Mannisto P.T. Site-specific role of catechol-o-methyltransferase in dopamine overflow within prefrontal cortex and dorsal striatum. J Neurosci 27 (2007) 10196-10209
212. Yee B.K., Hauser J., Dolgov V.V., Keist R., Möhler H., Rudolph U., et al. GABA receptors containing the alpha5 subunit mediate the trace effect in aversive and appetitive conditioning and extinction of conditioned fear. Eur J Neurosci 20 (2004) 1928-1936
213. Yee B.K., Keist R., von Boehmer L., Studer R., Benke D., Hagenbuch N., et al. A schizophrenia-related sensorimotor deficit links alpha 3-containing gabaa receptors to a dopamine hyperfunction. Proc Natl Acad Sci USA 102 (2005) 17154-17159
214. Young J.W., Crawford N., Kelly J.S., Kerr L.E., Marston H.M., Spratt C., et al. Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice. Eur Neuropsychopharmacol 17 (2007) 145-155
215. Young J.W., Powell S.B., Risbrough V., Marston H.M., and Geyer M.A. Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther 122 (2009) 150-202
216. Zhang Z., Sun J., and Reynolds G.P. A selective reduction in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia patients. Chin Med J 115 (2002) 819-823
217. Zhou X., Geyer M.A., and Kelsoe J.R. Does disrupted-in-schizophrenia (disc1) generate fusion transcripts?. Mol Psychiatry 13 (2008) 361-363
218. Zhou X., Long J.M., Geyer M.A., Masliah E., Kelsoe J.R., Wynshaw-Boris A., et al. Reduced expression of the sp4 gene in mice causes deficits in sensorimotor gating and memory associated with hippocampal vacuolization. Mol Psychiatry 10 (2004) 393-406
219. Zhou X., Tang W., Greenwood T.A., Guo S., He L., Geyer M.A., and Kelsoe J.R. Transcription factor SP4 is a susceptibility gene for bipolar disorder. PLosOne 4 (2009) e5196